A Phase 4 interventional study of Interferon beta-1a (Rebif) in Multiple Sclerosis, Relapsing-Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-02-27.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.
Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 14th largest by enrollment, is one of 4 that started in 2005, is one of 13 in phase 4, and was the 14th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 80 across the 21 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 8 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany: none open now, none under way, none of them phase 3. Of 39 finished, 20 (51%) have results posted.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, this one is the 17th largest by enrollment of the 21 interventional ones that give a count, is one of 7 that started in 2005, is one of 7 in phase 4, and was the 23rd registered.
Merck KGaA, Darmstadt, Germany’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 40 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In the course of therapy escalation, the multiple sclerosis (MS) subjects with high activity of disease receive mainly mitoxantrone. The duration of therapy is limited because of a cumulative dose for life (140 mg/m\^2 body surface area). In practice lower doses of mitoxantrone (60-120 mg/m\^2 body surface area) are being used. The specific reason for this limited total dose are potential cardiotoxic side effects of mitoxantrone. Once this cumulative dose of mitoxantrone is reached and the subject becomes stable, there is the question for subsequent therapy. A possibility at this time, is the so-called "de-escalation", therefore reducing the subject back to immunomodulating basic treatment.
The target of this open-label, randomised, multicentric, comparative, parallel-group study was to inquire systematically into the use and course of basic therapy with Rebif 44 mcg thrice weekly (tiw) for a larger number of subjects.
Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) and is one of the most common causes of neurological disability in young adults. It is characterised by multi-focal recurrent attacks of neurological symptoms and signs with variable recovery. Eventually, the majority of subjects develop a progressive clinical course. The exact cause of MS is unknown, although an autoimmune process has been implicated. Genetic susceptibility plays a role in disease initiation but unidentified environmental factors may also be involved. Three clinical forms of MS are recognized: primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS) and relapsing remitting multiple sclerosis (RRMS). Primary progressive subjects are characterised by slow and steady accumulation of neurological deficits from onset without superimposed attacks. Subjects with RRMS have exacerbations or relapses with subsequent variable recovery (remission). Secondary progressive multiple sclerosis is characterised by the steady accumulation of significant and persistent neurological deficit with or without superimposed relapses.
Rebif [recombinant interferon (IFN) beta-1a] has been tested in a series of studies in MS subjects at doses ranging from 22 mcg to 132 mcg weekly with a dose frequency ranging from weekly (qw) to tiw. Rebif has been found to be well tolerated in all clinical pharmacology studies, even at high doses (up to 66 mcg/m\^2). In later phase trials, Rebif has been tested across a broad range of doses, for varying duration, and in different stages of MS disease. Dose testing has ranged from 22 mcg to 132 mcg weekly with frequency of administration being qw to tiw.
OBJECTIVES
Primary objective:
Secondary objectives:
This was an open-label, randomised, multicentric, comparative, parallel-group study with a neurologist blinded to treatment for performing neurologic exams and a neuro-radiologist blinded to treatment for assessing central MRI scans. The study was divided into a screening phase (up to 28 days before the start of IFN-beta-1a treatment), a treatment phase of 96 weeks as well as a follow-up period of 4 weeks for subjects with ongoing serious adverse events (SAEs) at week 96. The study consisted of 2 groups to compare the therapeutic effect of high dose, high frequency IFN beta-1a therapy (Rebif 44 mcg) to subjects who will not be treated with Rebif 44 mcg. Subjects of both groups were previously treated with mitoxantrone in the \< 3 months prior to study inclusion. Subjects assigned to no treatment were switched to Rebif 44 mcg x 3 after reaching the primary endpoint or defined stopping criteria. The treatment period of this study begun with the completion of all baseline evaluations and the initiation of study drug treatment on Study Day 1 (baseline visit) and continues through until completion of the treatment period at the Week 96 visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects who must be neither pregnant nor breast-feeding and must lack , as defined by either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Interferon beta-1a (Rebif)
The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
Also known as: Rebif
Time From Baseline to First Multiple Sclerosis Relapse (in Weeks)
A qualifying relapse was defined as a new or worsening neurological symptom, in the absence of fever, lasting for \>= 48 hours, and accompanied by an objective change in the relevant (i.e. symptomatic) Kurtzke Functional Systems (KFS).
Time frame: Baseline through Week 96
Number of Relapse-free Participants
A qualifying relapse was defined as a new or worsening neurological symptom, in the absence of fever, lasting for \>= 48 hours, and accompanied by an objective change in the relevant (i.e. symptomatic) Kurtzke Functional Systems (KFS).
Time frame: Baseline through Week 96
Absolute Changes in the Number of T1 Lesions From Baseline to Week 24, 48, 72 and 96
Analysis of T1 lesions was done using magnetic resonance imaging (MRI) scans.
Time frame: Baseline to Week 24, 48, 72, and 96
Absolute Changes in the Number of T1-Gadolinium (T1-Gd) Lesions From Baseline to Week 24, 48, 72 and 96
Analysis of T1-Gadolinium enhancing lesions was done using magnetic resonance imaging (MRI) scans.
Time frame: Baseline to Week 24, 48, 72, and 96
Absolute Changes in the Number of T2 Lesions From Baseline to Week 24, 48, 72 and 96
Analysis of T2 lesions was done using magnetic resonance imaging (MRI) scans.
Time frame: Baseline to Week 24, 48, 72, and 96
Mean Changes in Expanded Disability Status Scale (EDSS) Score From Baseline to Week 12, 24, 36, 48, 60, 72, 84, and 96
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. EDSS progression was defined as increase by at least 1 point if last value of EDSS was equal to 5.5, and by at least 0.5 points if last EDSS was more than 5.5.
Time frame: Baseline to Week 12, 24, 36, 48, 60, 72, 84, and 96
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.
Time frame: Baseline to Week 96
Participants were enrolled at multiple centres in Germany.
| Milestone | Rebif 44 Mcg | No Treatment |
|---|---|---|
| Started | 15 | 15 |
| Completed | 12 | 13 |
| Not completed | 3 | 2 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
A qualifying relapse was defined as a new or worsening neurological symptom, in the absence of fever, lasting for \>= 48 hours, and accompanied by an objective change in the relevant (i.e. symptomatic) Kurtzke Functional Systems (KFS).
| weeks | Rebif 44 Mcg | No Treatment |
|---|---|---|
| Time From Baseline to First Multiple Sclerosis Relapse (in Weeks) | 35.5 ± 40.8 | 40.9 ± 28.7 |
A qualifying relapse was defined as a new or worsening neurological symptom, in the absence of fever, lasting for \>= 48 hours, and accompanied by an objective change in the relevant (i.e. symptomatic) Kurtzke Functional Systems (KFS).
| participants | Rebif 44 Mcg | No Treatment |
|---|---|---|
| Number of Relapse-free Participants | 10 | 7 |
Analysis of T1 lesions was done using magnetic resonance imaging (MRI) scans.
| T1 lesions | Rebif 44 Mcg | No Treatment |
|---|---|---|
| Week 24 (n= 13,15) | -0.5 ± 4.4 | -0.9 ± 8.9 |
| Week 48 (n= 13,13) | -0.8 ± 4.3 | 1.5 ± 11.2 |
| Week 72 (n= 12,12) | -0.8 ± 9.2 | -3.6 ± 12.0 |
| Week 96 (n= 12,12) | -1.8 ± 5.5 | -2.3 ± 11.6 |
Analysis of T1-Gadolinium enhancing lesions was done using magnetic resonance imaging (MRI) scans.
No measurements were reported for this outcome.
Analysis of T2 lesions was done using magnetic resonance imaging (MRI) scans.
| T2 lesions | Rebif 44 Mcg | No Treatment |
|---|---|---|
| Week 24 (n= 13,15) | -1.2 ± 4.0 | 1.0 ± 6.0 |
| Week 48 (n= 13,13) | 0.2 ± 8.5 | 3.2 ± 10.1 |
| Week 72 (n= 12,13) | -1.8 ± 3.3 | 3.1 ± 14.1 |
| Week 96 (n= 12,12) | -3.1 ± 7.6 | 2.1 ± 15.4 |
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. EDSS progression was defined as increase by at least 1 point if last value of EDSS was equal to 5.5, and by at least 0.5 points if last EDSS was more than 5.5.
| Units on a Scale | Rebif 44 Mcg | No Treatment |
|---|---|---|
| Week 12 (n= 14, 15) | -0.1 ± 0.5 | -0.1 ± 0.4 |
| Week 24 (n= 14, 15) | 0.3 ± 0.6 | 0.1 ± 0.4 |
| Week 36 (n= 13, 14) | 0.5 ± 0.8 | -0.2 ± 0.4 |
| Week 48 (n= 14, 14) | 0.5 ± 0.8 | 0.2 ± 0.7 |
| Week 60 (n= 10, 11) | 0.4 ± 0.8 | 0.0 ± 1.0 |
| Week 72 (n= 12, 13) | 0.3 ± 0.6 | 0.2 ± 0.9 |
| Week 84 (n= 12, 13) | 0.5 ± 0.9 | 0.2 ± 0.9 |
| Week 96 (n= 12, 13) | 0.1 ± 0.8 | 0.3 ± 1.0 |
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.
| participants | Rebif 44 Mcg | No Treatment |
|---|---|---|
| Adverse Events | 15 | 14 |
| Serious Adverse Events | 5 | 1 |
Collected over Baseline to Week 96 or premature termination or unscheduled visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rebif 44 Mcg | — | 5/15 (33.3%) | 15/15 (100%) |
| No Treatment | — | 1/15 (6.7%) | 14/15 (93.3%) |
| Event | Rebif 44 Mcg | No Treatment |
|---|---|---|
| ConvulsionNervous system disorders | 1/15 | 0/15 |
| Status EpilepticusNervous system disorders | 1/15 | 0/15 |
| Angle Closure GlaucomaEye disorders | 1/15 | 0/15 |
| Cholecystitis chronicHepatobiliary disorders | 1/15 | 0/15 |
| CholelithiasisHepatobiliary disorders | 1/15 | 0/15 |
| Haemorrhoid OperationGastrointestinal disorders | 1/15 | 0/15 |
| Gastroenteritis salmonellaGastrointestinal disorders | 1/15 | 0/15 |
| DepressionNervous system disorders | 0/15 | 1/15 |
| Event | Rebif 44 Mcg | No Treatment |
|---|---|---|
| NasopharyngitisInfections and infestations | 6/15 | 4/15 |
| HeadacheNervous system disorders | 4/15 | 2/15 |
| Influenza like illnessGeneral disorders | 3/15 | 2/15 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 3/15 |
| InfectionInfections and infestations | 3/15 | 0/15 |
| RhinitisInfections and infestations | 3/15 | 0/15 |
| Urinary tract infectionRenal and urinary disorders | 2/15 | 2/15 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/15 | 1/15 |
| Back PainMusculoskeletal and connective tissue disorders | 2/15 | 1/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/15 | 1/15 |
| Age, Continuous(years) | Rebif 44 Mcg | No Treatment | Total |
|---|---|---|---|
| Mean | 43.8 ± 7.0 | 44.3 ± 6.5 | 44.1 ± 6.6 |
| Sex: Female, Male(Participants) | Rebif 44 Mcg | No Treatment | Total |
|---|---|---|---|
| Female | 11 | 9 | 20 |
| Male | 3 | 6 | 9 |
| Expanded Disability Status Scale (EDSS)(Units on Scale) | Rebif 44 Mcg | No Treatment | Total |
|---|---|---|---|
| Mean | 4.1 ± 1.4 | 4.3 ± 1.0 | 4.2 ± 1.2 |
No study locations are listed for this record.
The record gives a start of Dec 2005, a primary completion of Dec 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Multiple Sclerosis, Relapsing-Remitting →
Merck KGaA, Darmstadt, Germany →